Scilex Holding Company (SCLX) 주식 분석

회사 개요

Scilex Holding Company is a specialized entity dedicated to the acquisition, development, and commercialization of non-opioid pain management solutions designed for both acute and chronic pain conditions. Operating within the Healthcare sector specifically as a Drug Manufacturers - General, the company focuses on delivering prescription pharmaceuticals such as ZTlido, a topical lidocaine system intended for pain relief. The firm currently maintains a market capitalization of $50.99M and employs 30 individuals to support its commercialization efforts. With an annual revenue of $40.36M, the company's valuation suggests it operates as a small-cap biotechnology firm, indicating a business model that relies on high-value specialized products rather than broad-scale mass market distribution.

재무 건전성

The company reported total revenue of $40.36M over the trailing twelve months, while simultaneously posting a net income loss of $375,835,008 and an EBITDA of $-259,160,000. The substantial discrepancy between the $40.36M revenue figure and the net income loss reveals a highly aggressive cost structure where operating expenses and other deductions significantly outweigh gross profits. Free cash flow stands at $-20,055,150, which indicates that the company is burning cash and lacks immediate financial flexibility to fund operations without external capital injections or asset monetization. The gross margin is reported at 68.6%, suggesting efficient production or pricing on its core products, yet the operating margin is severely negative at -1766.2% and the profit margin is 0.0%, highlighting that overhead costs are consuming all generated revenue. On the liquidity front, the company holds $878,000 in cash against $67.67M in debt, creating a precarious balance sheet where liabilities exceed assets significantly. The debt-to-equity ratio is listed as N/A due to the negative equity position, further emphasizing the leveraged nature of the firm. Additionally, the current ratio is 0.05, which signals a severe short-term liquidity crisis where current assets are only a fraction of current liabilities. Return on Equity is N/A because of the negative equity base, while the Return on Assets is -87.4%, indicating that the company's assets are generating substantial negative returns for its stakeholders.

밸류에이션 평가

The valuation metrics for Scilex Holding Company reflect a firm in distress with a trailing P/E ratio of N/A and a forward P/E of -8.15. The negative forward P/E implies that the market expects the company to remain unprofitable in the near term, preventing a meaningful comparison with earnings-based trailing multiples. The price-to-book ratio is -0.24, which indicates that the market is pricing the company at less than one-quarter of its book value, a common characteristic for firms with significant accumulated deficits or negative shareholder equity. Alternative valuation measures such as the price-to-sales ratio of 1.26 and an EV/EBITDA of -0.41 suggest that investors are valuing the firm primarily on its sales potential and future product pipeline rather than current profitability. The stock has traded between a 52-week low of $3.60 and a 52-week high of $34.27, meaning the current price sits significantly below the recent peak and reflects a deep correction from its 2024 highs. The beta of 1.42 indicates that the stock price is approximately 42% more volatile than the broader market, exposing investors to heightened risk during periods of market turbulence.

Growth & Income

Revenue growth year-over-year has contracted by 26.9%, while earnings growth is N/A given the lack of positive net income. The contraction in revenue suggests a decline in sales volume or pricing power, and since there are no positive earnings to support a faster growth rate, the firm is unable to leverage profitability to offset the revenue decline. As a non-dividend payer with a dividend yield of N/A and a payout ratio of 0.0%, the company does not distribute cash to shareholders but instead retains all capital, albeit insufficiently, to cover its operational deficits. This zero-payout profile is unsustainable in the traditional sense but reflects the company's inability to generate distributable income rather than a strategic choice to reinvest in growth. Overall, the growth and income profile is characterized by negative revenue expansion, deep losses, and an absence of dividend income, positioning the asset as a high-risk speculative investment reliant on future product successes to reverse its financial trajectory.